Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

[1] Giaid A(1995)Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 214-21

[2] Saleh D(1998)Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension Am J Respir Crit Care Med 158 1061-7

[3] Archer SL(2002)Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 2398-403

[4] Djaballah K(2004)Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebocontrolled, double-blind, crossover study J Am Coll Cardiol 43 1149-53

[5] Humbert M(2005)Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2148-57

[6] Weir KE(2006)A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension Am Heart J 151 851.e1-e5-903

[7] Fartoukh M(2009)Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2894-56

[8] Dall'ava-Santucci J(2012)Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials Circulation 126 349-16

[9] Michelakis E(2013)Updating clinical endpoint definitions Pulm Circ 3 206-83

[10] Tymchak W(2011)Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study Chest 140 1274-54

[1] Giaid A(1995)Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 214-21

[2] Saleh D(1998)Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension Am J Respir Crit Care Med 158 1061-7

[3] Archer SL(2002)Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 2398-403

[4] Djaballah K(2004)Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebocontrolled, double-blind, crossover study J Am Coll Cardiol 43 1149-53

[5] Humbert M(2005)Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2148-57

[6] Weir KE(2006)A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension Am Heart J 151 851.e1-e5-903

[7] Fartoukh M(2009)Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2894-56

[8] Dall'ava-Santucci J(2012)Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials Circulation 126 349-16

[9] Michelakis E(2013)Updating clinical endpoint definitions Pulm Circ 3 206-83

[10] Tymchak W(2011)Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study Chest 140 1274-54